Pulmonx Corporation (LUNG) Stock Analysis & Winston Score

Pulmonx Corporation makes a small medical device called the Zephyr Endobronchial Valve. This valve is placed inside the lungs of patients with severe emphysema, a lung disease that makes it very hard to breathe. Doctors at hospitals and specialty clinics use the device as a less invasive alternative to surgery for these patients. The company earns revenue by selling these single-use valves to hospitals, which means each procedure generates a new sale. Pulmonx operates primarily in the United States and select European markets, and its main competitive advantage is that the Zephyr Valve is the only FDA-approved endobronchial valve for emphysema treatment in the US. However, the company is still losing significant money — its operating margin is deeply negative — and the key challenge ahead is expanding the number of trained physicians and approved treatment centers to grow procedure volumes fast enough to reach profitability.